NCT03839524View on ClinicalTrials.gov

A Trial Evaluating TG4050 in Ovarian Carcinoma.

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Ovarian CarcinomaFallopian Tube CancerPeritoneal Carcinoma
Interventions
DRUG

TG4050

Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.

Trial Locations (6)

31100

IUCT Toulouse, Toulouse

32224

Mayo Clinic Jacksonville, Jacksonville

55905

Mayo Clinic Rochester, Rochester

75005

Institut Curie, Paris

75013

Hôpital Pitié-Salpêtrière, Paris

85259

Mayo Clinic Phoenix, Phoenix

Sponsors

Lead Sponsor

Transgene
All Listed Sponsors
lead

Transgene

INDUSTRY

NCT03839524 - A Trial Evaluating TG4050 in Ovarian Carcinoma. | Biotech Hunter | Biotech Hunter